On December 30, Immedica Pharma announced that it acquired Marinus Pharmaceuticals, Inc. for approximately $151 million.
Immedica will acquire all the outstanding shares of Marinus common stock for a cash purchase price of $0.55 per share, representing a premium of 48% based on Marinus’ closing share price as of December 27th and a premium of 97%, based on the 30-day volume-weighted average price of $0.28 per share preceding the announcement of the transaction.
Marinus is a commercial-stage pharmaceutical company dedicated to the development of innovative therapeutics for seizure disorders. The Company’s product, ZTALMY® (ganaxolone) oral suspension CV, is an FDA-approved prescription medication introduced in the United States in 2022.
Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica’s capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. In early 2024, Immedica was purchased by private equity group KKR & Co. Inc.
MTS Health Partners LP is acting as Immedica’s exclusive financial advisor. Gibson, Dunn & Crutcher LLP is acting as legal counsel to Immedica and Fuchs Patentanwälte Partnerschaft mbB is acting as intellectual property counsel. Barclays Capital Inc. is acting as Marinus´ exclusive financial advisor. Hogan Lovells LLP is acting as legal counsel to Marinus.
The acquisition is expected to accelerate Immedica’s revenue growth, adding a commercial-stage asset in the United States, with the potential for further expansion globally. It is expected to close in Q1 2025.
According to data in the LevinPro HC database, this transaction marks the 64th Pharmaceuticals transaction of 2024. In 2023, 107 Pharmaceuticals transactions were announced.
